Tempus AI increased its convertible senior notes offering from $400 million to $650 million to manage debt and reduce interest expenses. The Chicago-based precision medicine company offered notes due 2030 with a conversion rate equivalent to an $84.19 share price. Net proceeds are expected to exceed $625 million, possibly rising to $721 million with over-allotments. Despite ongoing litigation over management statements, Tempus aims to use the capital to repay secured loans and pursue general corporate purposes.